J&J/Merck Pepcid AC Orally Disintegrating Tablets In The Works
This article was originally published in The Tan Sheet
Executive Summary
J&J/Merck is looking to extend its category-leading Pepcid AC franchise with an orally disintegrating dosage form developed by Yamanouchi Pharma Technologies.
You may also be interested in...
H2s
Famotidine orally disintegrating tablets cleared for ANDA submission by FDA in April 17 letter to Yamanouchi Pharma; firm filed citizen petition in July requesting authorization to change dosage form of J&J/Merck's Pepcid AC (1"The Tan Sheet" Aug. 7, 2000, p. 3). Pepcid AC lost exclusivity April 15. Also, agency gives green light to ANDA filing for generic nizatidine. Lachman Consultant Services filed citizen petition in April 2000 on behalf of unnamed drug maker to permit application for private label capsule form of Whitehall-Robins' Axid AR, for which exclusivity expired April 1. Leiner recently said it would not file an ANDA due to perceived lack of demand (2"The Tan Sheet" April 2, In Brief)
Glaxo Zantac 75 Divestiture To W-L Required By FTC
Glaxo Wellcome has agreed to sell trademark rights and other controls over the marketing of OTC Zantac 75 to Warner-Lambert Consumer Group in order to complete its merger with SmithKline Beecham in accordance with a proposed consent order issued by the Federal Trade Commission Dec. 18.
Generic Famotidine Launch Delayed By Pepcid AC Pediatric Exclusivity
Private label famotidine 10 mg products will not launch until after April 15 due to FDA's Nov. 21 decision to grant J&J/Merck an additional six months of marketing exclusivity for Pepcid AC after reviewing pediatric data submitted by the firm.